A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
复制标题

DOI:
10.1038/nchembio.332
复制
发表时间:
2010-04
影响因子:
14.8
通讯作者:
Haura, Eric B.
Haura, Eric B.
中科院分区:
生物学1区
文献类型:
--
作者:
Li, Jiannong;Rix, Uwe;Fang, Bin;Bai, Yun;Edwards, Arthur;Colinge, Jacques;Bennett, Keiryn L.;Gao, Jingchun;Song, Lanxi;Eschrich, Steven;Superti-Furga, Giulio;Koomen, John;Haura, Eric B.

文献摘要

参考文献

被引文献

相似文献

我们描述了一种策略,以了解在肺癌细胞中活跃的信号通路,并采用化学蛋白质组学,以确定直接相互作用的蛋白质结合免疫亲和纯化的酪氨酸磷酸化肽对应于激活的酪氨酸激酶为目标的达沙替尼。我们鉴定了达沙替尼的近40种不同激酶靶点。这些包括SFK成员(林恩、SRC、FYN、LCK、YES)、非受体酪氨酸激酶(FRK、BRK、ACK)和受体酪氨酸激酶(肝配蛋白受体、DDR1、EGFR)。使用定量磷酸蛋白质组学,我们鉴定了与这些酪氨酸激酶的自磷酸化位点对应的肽,这些酪氨酸激酶以浓度依赖性方式被达沙替尼抑制。使用耐药看门突变体,我们表明SFK激酶,特别是SRC和FYN,以及EGFR是达沙替尼作用的相关靶点。本文描述的基于质谱的组合方法提供了达沙替尼在癌细胞中作用的系统水平视图,并提出了功能靶标和基本组合治疗策略。
We describe a strategy to comprehend signaling pathways active in lung cancer cells and targeted by dasatinib employing chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine phosphorylated peptides corresponding to activated tyrosine kinases. We identified nearly 40 different kinase targets of dasatinib. These include SFK members (LYN, SRC, FYN, LCK, YES), non-receptor tyrosine kinases (FRK, BRK, ACK), and receptor tyrosine kinases (Ephrin receptors, DDR1, EGFR). Using quantitative phosphoproteomics we identified peptides corresponding to autophosphorylation sites of these tyrosine kinases that are inhibited in a concentration-dependent manner by dasatinib. Using drug resistant gatekeeper mutants, we show that SFK kinases, particularly SRC and FYN, as well as EGFR are relevant targets for dasatinib action. The combined mass spectrometry based approach described here provides a system-level view of dasatinib action in cancer cells and suggests both functional targets and rationale combinatorial therapeutic strategies.
DOI: 10.1056/nejmoa040938
发表时间: 2004-05-20
影响因子: 158.5
作者:
Lynch, TJ;Bell, DW;Haber, DA
通讯作者: Haber, DA
DOI: 10.1038/sj.bjc.6603614
发表时间: 2007-03-12
影响因子: 8.8
作者:
通讯作者: --
DOI: 10.1038/sj.onc.1210684
发表时间: 2008-02-07
期刊: ONCOGENE
影响因子: 8
作者:
Fu, Y-N;Yeh, C-L;Chen, Y-R
通讯作者: Chen, Y-R
DOI: 10.1073/pnas.92.15.6981
发表时间: 1995-07-18
影响因子: 11.1
作者:
MAA, MC;LEU, TH;PARSONS, SJ
通讯作者: PARSONS, SJ
DOI: 10.1038/nbt.1513
发表时间: 2009-01
影响因子: 46.9
作者:
Du, Jinyan;Bernasconi, Paula;Clauser, Karl R.;Mani, D. R.;Finn, Stephen P.;Beroukhim, Rameen;Burns, Melissa;Julian, Bina;Peng, Xiao P.;Hieronymus, Haley;Maglathlin, Rebecca L.;Lewis, Timothy A.;Liau, Linda M.;Nghiemphu, Phioanh;Mellinghoff, Ingo K.;Louis, David N.;Loda, Massimo;Carr, Steven A.;Kung, Andrew L.;Golub, Todd R.
通讯作者: Golub, Todd R.